Biochemistry and Cell Biology of Tau Protein in Neurofibrillary Degeneration

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2012 Jul 5

PMID 22762014

Citations 385

Authors

Eva-Maria Mandelkow

Eckhard Mandelkow

Affiliations

Soon will be listed here.

Abstract

Tau represents the subunit protein of one of the major hallmarks of Alzheimer disease (AD), the neurofibrillary tangles, and is therefore of major interest as an indicator of disease mechanisms. Many of the unusual properties of Tau can be explained by its nature as a natively unfolded protein. Examples are the large number of structural conformations and biochemical modifications (phosphorylation, proteolysis, glycosylation, and others), the multitude of interaction partners (mainly microtubules, but also other cytoskeletal proteins, kinases, and phosphatases, motor proteins, chaperones, and membrane proteins). The pathological aggregation of Tau is counterintuitive, given its high solubility, but can be rationalized by short hydrophobic motifs forming β structures. The aggregation of Tau is toxic in cell and animal models, but can be reversed by suppressing expression or by aggregation inhibitors. This review summarizes some of the structural, biochemical, and cell biological properties of Tau and Tau fibers. Further aspects of Tau as a diagnostic marker and therapeutic target, its involvement in other Tau-based diseases, and its histopathology are covered by other chapters in this volume.

Citing Articles

Inspecting the Triazole Scaffold as Powerful Antifibril Agents against 2N4R Tau and α-Synuclein Aggregates.

Elbatrawy A, Ademoye T, Alnakhala H, Tripathi A, Zhu X, Plascencia-Villa G ACS Omega. 2025; 10(7):6721-6734.

PMID: 40028124 PMC: 11866179. DOI: 10.1021/acsomega.4c08385.

Temperature-Dependent Aggregation of Tau Protein Is Attenuated by Native PLGA Nanoparticles Under in vitro Conditions.

Paul P, Rathnam M, Khalili A, Cortez L, Srinivasan M, Planel E Int J Nanomedicine. 2025; 20:1999-2019.

PMID: 39968061 PMC: 11834738. DOI: 10.2147/IJN.S494104.

Selenoproteins: Zoom-In to Their Metal-Binding Properties in Neurodegenerative Diseases.

Duta C, Muscurel C, Dogaru C, Stoian I Int J Mol Sci. 2025; 26(3).

PMID: 39941073 PMC: 11818150. DOI: 10.3390/ijms26031305.

Structural insights into the role of the proline rich region in tau function.

Acosta K, Brue C, Holubovska P, Kim H, Mayne L, Murakami K Structure. 2025; 33(3):465-474.e8.

PMID: 39826549 PMC: 11890945. DOI: 10.1016/j.str.2024.12.017.

Localized Reconstruction of Multimodal Distance Distribution from DEER Data of Biopolymers.

Tsay K, Keller T, Fichou Y, Freed J, Han S, Srivastava M bioRxiv. 2025; .

PMID: 39803469 PMC: 11722431. DOI: 10.1101/2025.01.02.631084.

References

Crowther R, Olesen O, Smith M, Jakes R, Goedert M . Assembly of Alzheimer-like filaments from full-length tau protein. FEBS Lett. 1994; 337(2):135-8. DOI: 10.1016/0014-5793(94)80260-2. View

Goedert M, Wischik C, Crowther R, Walker J, Klug A . Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A. 1988; 85(11):4051-5. PMC: 280359. DOI: 10.1073/pnas.85.11.4051. View

Ishihara T, Higuchi M, Zhang B, Yoshiyama Y, Hong M, Trojanowski J . Attenuated neurodegenerative disease phenotype in tau transgenic mouse lacking neurofilaments. J Neurosci. 2001; 21(16):6026-35. PMC: 6763173. View

Brion J, Couck A, Passareiro E, FLAMENT-DURAND J . Neurofibrillary tangles of Alzheimer's disease: an immunohistochemical study. J Submicrosc Cytol. 1985; 17(1):89-96. View

Sontag E, Lee G, Brandt R, Kamibayashi C, Kuret J, White 3rd C . Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J Biol Chem. 1999; 274(36):25490-8. DOI: 10.1074/jbc.274.36.25490. View

Planel E, Tatebayashi Y, Miyasaka T, Liu L, Wang L, Herman M . Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci. 2007; 27(50):13635-48. PMC: 6673606. DOI: 10.1523/JNEUROSCI.3949-07.2007. View

Goedert M, Ghetti B, Spillantini M . Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med. 2012; 2(2):a006254. PMC: 3281593. DOI: 10.1101/cshperspect.a006254. View

Poorkaj P, Bird T, Wijsman E, Nemens E, Garruto R, Anderson L . Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998; 43(6):815-25. DOI: 10.1002/ana.410430617. View

Mandelkow E, Thies E, Trinczek B, Biernat J, Mandelkow E . MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J Cell Biol. 2004; 167(1):99-110. PMC: 2172520. DOI: 10.1083/jcb.200401085. View

10.

Moores C, Perderiset M, Francis F, Chelly J, Houdusse A, Milligan R . Mechanism of microtubule stabilization by doublecortin. Mol Cell. 2004; 14(6):833-9. DOI: 10.1016/j.molcel.2004.06.009. View

11.

Obar R, Collins C, Hammarback J, Shpetner H, Vallee R . Molecular cloning of the microtubule-associated mechanochemical enzyme dynamin reveals homology with a new family of GTP-binding proteins. Nature. 1990; 347(6290):256-61. DOI: 10.1038/347256a0. View

12.

Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow E . Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry. 1999; 38(12):3549-58. DOI: 10.1021/bi981874p. View

13.

SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M . Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005; 309(5733):476-81. PMC: 1574647. DOI: 10.1126/science.1113694. View

14.

Gauthier-Kemper A, Weissmann C, Golovyashkina N, Sebo-Lemke Z, Drewes G, Gerke V . The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner. J Cell Biol. 2011; 192(4):647-61. PMC: 3044115. DOI: 10.1083/jcb.201007161. View

15.

Sun W, Qureshi H, Cafferty P, Sobue K, Agarwal-Mawal A, Neufield K . Glycogen synthase kinase-3beta is complexed with tau protein in brain microtubules. J Biol Chem. 2002; 277(14):11933-40. DOI: 10.1074/jbc.M107182200. View

16.

Berriman J, Serpell L, Oberg K, Fink A, Goedert M, Crowther R . Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci U S A. 2003; 100(15):9034-8. PMC: 166433. DOI: 10.1073/pnas.1530287100. View

17.

Myers A, Pittman A, Zhao A, Rohrer K, Kaleem M, Marlowe L . The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis. 2006; 25(3):561-70. DOI: 10.1016/j.nbd.2006.10.018. View

18.

Chirita C, Congdon E, Yin H, Kuret J . Triggers of full-length tau aggregation: a role for partially folded intermediates. Biochemistry. 2005; 44(15):5862-72. DOI: 10.1021/bi0500123. View

19.

Chambraud B, Sardin E, Giustiniani J, Dounane O, Schumacher M, Goedert M . A role for FKBP52 in Tau protein function. Proc Natl Acad Sci U S A. 2010; 107(6):2658-63. PMC: 2823896. DOI: 10.1073/pnas.0914957107. View

20.

Gotz J, Deters N, Doldissen A, Bokhari L, Ke Y, Wiesner A . A decade of tau transgenic animal models and beyond. Brain Pathol. 2007; 17(1):91-103. PMC: 8095624. DOI: 10.1111/j.1750-3639.2007.00051.x. View